Work

Bacillus calmette-guérin failures and beyond: contemporary management of non-muscle-invasive bladder cancer.

Year: 2008

Type: article

Abstract: In the United States, bacillus Calmette-Guérin (BCG) is the treatment most used for superficial bladder cancer. Patients with carcinoma in situ (CIS) treated with intravesical BCG plus interferon have a 60% to 70% chance of a complete and durable response if they were never treated with BCG or if they failed only 1 prior induction or relapsed more than a year from induction. Intravesical gemcitabine is safe, but its usefulness for BCG-refractory patients is unclear. Valrubicin, approved for intravesical treatment of BCG-refractory CIS of the bladder, has efficacy and acceptable toxicity. Cystectomy should be considered in high-risk, non-muscle-invasive cancer, particularly if intravesical therapy failed.

Source: Europe PMC (PubMed Central)

Authors: H Barton Grossman, Michael A O'Donnell, Michael S Cookson, Richard E Greenberg, Thomas E Keane

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W61550010

FWCI: 4.022

Cites: 34

Cited by: 32

Related to: 10